Фортека - analogs
Components: Prolgolimab |
|||||||||
Pharmgroups: Antitumor agents - monoclonal antibodies |
|||||||||
| Prices in pharmacies: 980€ Instructions Фортека | |||||||||
|
ⓘ✘Enter drugs for checking interactions through a quick button search . Conus pulcher ✘ (incl) Groprinosin-Richter ✘ (incl) Дэглюнорм ✘ (incl) Actrapid HM Penfill ✘ (incl) Oxyfedrine ✘ (incl) Rozistark ✘ (incl) Vero-Vinblastine aqueous ✘ (incl) Сантабрим ✘ (incl) Benzobamil ✘ (incl) Илпион ✘ (incl) Oestrogel ✘ (incl) Аллерген эпидермальный из шерсти кошки для диагностики ✘ (incl) Oprelvekin ✘ (incl) Vero-Ciprofloxacin ✘ (incl) Vero-Pipecuronium ✘ |
|
ⓘ✘ diseases to evaluate contraindications and side effects through a quick search. | ||||||
Начиная работу с сервисом, вы принимаете соглашение пользователя. Kiberis do not replace the doctor!
| Similar | Complete analog ⓘ✘Analogues of the drug with completely identical active ingredients |
Prices in pharmacies |
| ≈100% | neutral Nurulimab+Prolgolimab |
-
Similar
Prices in
pharmaciesAnalogs by action ⓘ✘Analogues of the drug according to its degree of similarity with other drugs that are not direct analogues
- 70% — Нурдати neutral [Nurulimab+Prolgolimab and more 1Prolgolimab]
- 40% 1750€ Tafinlar neutral [Dabrafenib]
- 40% 630-1550€ Cotellic neutral [Cobimetinib]
- 36% 3603.1€ Ервой neutral [Ipilimumab]
- 35% — Персинтия neutral [Pertuzumab]
- 35% — Пертувиа neutral [Pertuzumab]
- 30% — Лапатиниб neutral [Lapatinib]
- 30% — Бейодайм neutral [Pertuzumab+Trastuzumab and more 2Pertuzumab, Trastuzumab]
- 30% 899.2-1145€ Tyverb neutral [Lapatinib]
- 30% — Витракви neutral [Larotrectinib]
- 30% — Лапатиниба дитозилат моногидрат neutral [Lapatinib]
- 30% — Энзаклуд neutral [Enzalutamide]
- 30% — Лапатиниб-АМЕДАРТ neutral [Lapatinib]
- 30% 8.7€ Bicalutamid-Kabi neutral [Bicalutamide]
- 30% — Энзалутамид-АМЕДАРТ neutral [Enzalutamide]
- 30% — Энзалутамид-Промомед neutral [Enzalutamide]
- 30% — Апалатиб neutral [Lapatinib]
- 30% — Лапатиниб-промомед neutral [Lapatinib]
- 28% 570€ Bavencio neutral [Avelumab]
- 28% — Remobav neutral [Catumaxomab]
- 28% — Теквэйли neutral [Teclistamab]
- 25% 210.1€ Сарклиза neutral [Isatuximab]
- 25% 1045€ Imfinzi neutral [Durvalumab]
- 24% 108-345.8€ Тразимера neutral [Trastuzumab]
- 24% 11-11.6€ Anastrozole-Kabi neutral [Anastrozole]
- 24% — Гефитиниб-промомед neutral [Gefitinib]
- 24% — Нубека neutral [Darolutamide]
- 24% 125-350€ Herticad neutral [Trastuzumab]
- 24% — Hexvix neutral [Hexylaminolevulinate]
- 24% 220€ Trastuzumab neutral [Trastuzumab]
- 24% — Гефитиниб-Рус neutral [Gefitinib]
- 24% — Кабазред neutral [Cabazitaxel]
- 24% 920.2-1540.1€ Erleada neutral [Apalutamide]
- 24% — Афатиниб neutral [Afatinib]
- 24% — Uro-BCG-medac neutral [Vaccinum for immunotherape cancer of vesica urinaria]
- 24% 27.2€ Imuron-vac neutral [Vaccinum for immunotherape cancer of vesica urinaria]
- 24% — Афатиниб Фармасинтез neutral [Afatinib]
- 24% — Эриблиус neutral [Eribulin]
- 24% — Эрибулин-АМЕДАРТ neutral [Eribulin]
- 24% — Афатиниб-промомед neutral [Afatinib]
- 23% 2075€ Blincyto neutral [Blinatumomab]
- 23% 748.1€ Empliciti neutral [Elotuzumab]
- 23% — Обинутузумаб neutral [Obinutuzumab]
- 23% 394.8€ Mustophoran neutral [Fotemustine]
- 23% 8873.4€ Besponsa neutral [Inotuzumab ozogamicin]
- 23% 118.5-850.3€ Herceptin neutral [Trastuzumab]
- 23% — Имджудо neutral [Tremelimumab]
- 23% — Мектови neutral [Binimetinib]
- 23% — Пембролизумаб neutral [Pembrolizumab]
- 23% 1064.8€ Арфлейда neutral [Pembrolizumab]
Learn more about the selection of analogues
▶
- The drug has «Фортека» 1 full analog, for example Nurulimab+Prolgolimab; 51 analog by action, the most similar - Tafinlar (1750€).
- Medical online service has selected the best substitutes for Фортека based on its instructions, components, pharmaceutical groups and practical application.
- The table shows the prices of analogues Фортека to choose the cheapest pills.
- If you have introduced other drugs for registration, substitutes are selected taking into account the assessment of interactions and safety.
- Sometimes, due to the presence of dangerous interactions, it is necessary to use drugs that are similar in effect, sometimes even from different pharmacological groups.